Check out Dr. Lorenza Rimassa Lorenza Rimassa discussing #ESMO23 'HCC and Cholangiocarcinoma Mini Orals Highlights'

#livercancer #HCC #biliarytractcancer #cholangiocarcinoma #GICSM
Full video on #VuMedi
👇
bit.ly/ESMO23orals

'Compass Therapeutics Provides Corporate Update'
Read the news release at: ow.ly/RBoB50Qoj8y
#CMPX #biotech #biotech nology #cancer #healthcare #biliarytractcancer #colorectalcancer #smallcelllungcancer

Check out Dr. Lorenza Rimassa Lorenza Rimassa
discussing #ESMO23 'Personalized Medicine and Targeted Agents for Biliary Tract Cancer'

#livercancer #HCC #biliarytractcancer #GICSM
Full video on #VuMedi
👇
bit.ly/ESMO23BTC

I'm happy to share that our latest editorial on targeted therapies in biliary tract cancers is now published:
dx.doi.org/10.21037/c
#cancer #oncology #precisionmedicine #targetedtherapy #precisiononcology #biliarytractcancer

A meta-analysis on biliary tract cancer shows the modified Glasgow prognostic score (mGPS) is linked to worse survival outcomes. Highlighting the need for tailored treatments. #BiliaryTractCancer #CancerPrognosis #Oncology #ClinicalResearch

Exciting news!
Our review article on 'The Role of HER2 Status in Biliary Tract Cancers' has been published in Cancers MDPI *. Congratulations to Ruveyda Ayasun, MD/PhD and Muhammet Ozer for their valuable contributions to this important topic. #HER2 #biliarytractcancer
UF Health Cancer Center

🔥Frontline studies in #biliarytractcancer
@ ASCO-GI
👏Excellent discussion by Imane H. El Dika

ESMO - Eur. Oncology EASL Education #livertwitter ENS-CCA

There are numerous ways to manage and treat Biliary Tract Cancer (BTC). Right information and awareness is the key to correct diagnosis and treatment.
#BiliaryTractCancer #BiliaryTractCancer Awareness #CancerAwareness #AstraZeneca

🔥Trastuzumab/ FOLFOX for HER2+ #biliarytractcancer
The Lancet Oncology
doi.org/10.1016/S2468-…
✅KCSG-HB19–14 🇰🇷phs-2 34 pts
👉ORR 30%, mPFS 5.1mo mOS 10.7mo
🧐Multiple🎯options: T +/-Pertuzumab or CTx, T-DXd, Neratinib, Zanidatamab... Which 💊is 🥇?
ESMO - Eur. Oncology EASL Education #livertwitter

#BiliaryTractCancer is a rare disease with poor prognosis. GemCisDurva is a new standard Tx #TOPAZ1 No definitive markers for response and resistance. Seeking immune exclusion markers from diff cells (AOI) at diff regions (ROI) by spatial transcriptomics #SITC23 Eileen M O’Reilly

🔥Final Analysis From a Phs 2b Study of Liposomal Irinotecan Plus Fluorouracil & LV for Previously Treated Metastatic #BiliaryTractCancer
JAMA Oncology
doi.org/10.1001/jamaon…
😕Unfortunately, not confirmed in our NALIRICC study👇doi.org/10.1016/j.anno…
ESMO - Eur. Oncology EASL Education #LiverTwitter

1/3🚀JHEP Twittorial🚀

🍀The risk of #BiliaryTractCancer (BTC)🦀 is also in our genome❗️

🔓 #OpenAccess 👉bit.ly/3rSovm2

👉Most BTCs are sporadic..🤔

BUT: factors inducing ⏫(PSC; stones; cirrhosis) or ⬆️ (👴🧓,🍔🚬🍸) risk are well established

Here,🇯🇵👇
#LiverTwitter

Highlights in 2023 ESMO congress biliary tract cancer session #ESMO23 ESMO - Eur. Oncology
@innov_medicine @the_innovationJ

ESMO 2023 Insights: Revolutionizing BTC Treatment! From pioneering immunotherapy in neoadjuvant BTC to exploring AI in research. #BiliaryTractCancer …

Pooled data of 2 Ph/II trials of #KRASG12C inhibitor glecirasib in adv solid tumors (59.6% #PDAC ) ORR 42% in met PDAC, 71.4% in #biliarytractcancer , 67% in #gastriccancer #GI24 OncoAlert median PFS 5.6 mo for #PDAC cohort

Our #MedicalOncology keynote is from Prof Niall Tebbutt on Managing Advanced #BiliaryTractCancer in the Era of #PrecisionMedicine , discussing current practice and future directions in #CCA , including his new #AGITG trial in development #BILPPP

Oggi e domani a Roma si terrà News in GI & GU Oncology 2024.
Consulta qui il programma > aiom.it/.../2024_03_01…

#AIOM #Gastroesophagealcancer #Pancreaticcancer #biliarytractcancer #GastrointestinalCancer #Genitourinaryoncology

Insights from the KCSG-HB19-14 trial in The Lancet Gastroenterology & Hepatology *! Our commentary highlights the importance of considering somatic HER2 alterations in the context of trastuzumab plus FOLFOX for HER2+ #biliarytractcancer patients.
Ruveyda Ayasun, MD/PhD
UF Health Cancer Center #personalizedmedicine

The risk of #BiliaryTractCancer (BTC) is also in our genome❗️

🔎Hereditary #cancer -predisposing gene alterations were identified in 5.5% of BTCs
➡️including in #BRCA & genes associated with #colorectalcancer

🔓 #OpenAccess at👉bit.ly/3rSovm2

#LiverTwitter

The road to #GI23 is long and arduous but ultimately worth it. I don’t think I’ve had an on time flight in 6 months. Can you tell I look thrilled? ASCO ASCOPost #HCC #biliarytractcancer

📍TTD #RETUD Metaanalysis suggests PFS serve as a surrogate for OS in advanced #BiliaryTractCancer .
PFS&OS show correlation on trial/individual levels. HR<0.69 in PFS might indicate substantial OS benefit

Kudos to our superb team Teresa Macarulla Carles Fabregat-Franco Florian Castet